BP lowering with amlodipine and lipid lowering with atorvastatin still resulted in lower rates of stroke and CV death in hypertensive patients after more than a decade, as the results of a long-term follow-up of data from the ASCOT trial show.
In patients with a systolic BP between 120 and <140 mmHg, a diastolic BP between 70 and <80 mmHg was associated with a lower risk of adverse outcomes as compared to lower and higher DBP.
An observational study showed longer consultations with minimal shared-decision making behavior by GPs during daily practice in 2015 compared with 2007, with less shared-decision making behavior in older patients.
The new guidelines on management of CVD during pregnancy consider new evidence on diagnostic techniques, risk assessment and drug therapy that became available since the 2012 edition.
One third of patients with newly diagnosed hypertension in this study required more than 125 days for their BP to be controlled. A longer delay in BP control was independently associated with all-cause mortality.
The prospective Copenhagen Male study followed men for 46 years and showed that cardiorespiratory fitness is dose-dependently associated with longevity in middle-aged men without CVD.
ESC 2018 In this debate, the different viewpoints supporting the European and American Guidelines on Hypertension were fiercely defended, although overlap prevails.
ESC 2018 Dr Allard-Ratick tells about the surprising result that HDL-C levels >60 mg/dl (1.5 mmol/L) were associated with a nearly two-fold increase in the risk of CV death or MI in adults with CV disease.
ESC 2018 In an analysis of four large global studies, higher healthy diet score was related to a lower risk of mortality, MI and stroke. Dr. Mente discusses how the healthy diet score is calculated and talks about the results of these four studies.
ESC 2018 In overweight or obese patients with CVD or diabetes with one CV risk factor, lorcaserin demonstrated to be safe with respect to CV outcomes. Dr. Bohula discussed the implications of the CAMELLIA-TIMI 61 trial.
ESC 2018 Although aspirin resulted in a reduction of CV events in a primary prevention setting of diabetes patients, this CV benefit was counterbalanced by an increase in bleeding.
ESC 2018 Use of omega-3 fatty acid supplements did not result in reduction of CV outcomes in the ASCEND trial, a large, randomized, long-term trial of diabetes patients.